| Alessandro Papa, MD | |
|
19 Friendship St, Suite 360, Newport, RI 02840-2200 | |
| (401) 845-1998 | |
| (401) 848-6510 |
| Full Name | Alessandro Papa |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 40 Years |
| Location | 19 Friendship St, Newport, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295725141 | NPI | - | NPPES |
| 30-00139 | Other | RI | UNITED HEALTH CARE |
| 004325 | Other | RI | BLUECHIP |
| 9020077 | Medicaid | RI | |
| 0595617 | Other | RI | AETNA |
| 20077 | Other | RI | BLUE CROSS/BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | RI7288 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| Newport Hospital | Newport, RI | Hospital |
| The Miriam Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rhode Island Hospital | 8921900044 | 303 |
News Archive
Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.
In an attempt to determine what factors make one nanoparticle better than another at targeting tumors, a team of investigators in Korea have conducted a systematic tumor-targeting study of a variety of self-assembling nanoparticles.
Some benefits of motherhood are intangible, but one has been validated through biostatistical research: women who bear children have a reduced risk of developing breast cancer.
Scientists at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have made a significant breakthrough in the fight against Membranous Nephropathy (MN) - a rare kidney disease which can lead to kidney failure.
› Verified 7 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396849782 PECOS PAC ID: 8921900044 Enrollment ID: O20050211000311 |
News Archive
Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.
In an attempt to determine what factors make one nanoparticle better than another at targeting tumors, a team of investigators in Korea have conducted a systematic tumor-targeting study of a variety of self-assembling nanoparticles.
Some benefits of motherhood are intangible, but one has been validated through biostatistical research: women who bear children have a reduced risk of developing breast cancer.
Scientists at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have made a significant breakthrough in the fight against Membranous Nephropathy (MN) - a rare kidney disease which can lead to kidney failure.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alessandro Papa, MD 19 Friendship St, Suite 360, Newport, RI 02840-2200 Ph: (401) 845-1998 | Alessandro Papa, MD 19 Friendship St, Suite 360, Newport, RI 02840-2200 Ph: (401) 845-1998 |
News Archive
Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.
In an attempt to determine what factors make one nanoparticle better than another at targeting tumors, a team of investigators in Korea have conducted a systematic tumor-targeting study of a variety of self-assembling nanoparticles.
Some benefits of motherhood are intangible, but one has been validated through biostatistical research: women who bear children have a reduced risk of developing breast cancer.
Scientists at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have made a significant breakthrough in the fight against Membranous Nephropathy (MN) - a rare kidney disease which can lead to kidney failure.
› Verified 7 days ago
Daniela Mccooey, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11 Friendship St, Newport, RI 02840 Phone: 401-845-1281 | |
Dr. John Thomas Mccaffrey, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 409 Broadway, Newport, RI 02840 Phone: 401-849-1280 Fax: 401-847-2815 | |
Brandon Forrest Boldt, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 293 Kollmeyer St, Newport, RI 02841 Phone: 401-841-7987 | |
Dr. Ralph Thomas Earp, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 50 Memorial Blvd, Aquidneck Medical Associates, Newport, RI 02840 Phone: 401-847-2290 Fax: 401-849-8446 | |
Dr. Danielle Saldin, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11 Friendship St, Newport, RI 02840 Phone: 401-845-4265 | |
Irina Chernaya, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11 Friendship St, Newport, RI 02840 Phone: 401-846-6400 |